The ongoing impact of COVID-19 on health services across Europe has led to significant reductions in cancer screening, testing and diagnosis. Delays in diagnosis are already impacting cancer treatment and survival and are likely to continue for years to come. Responses to the pandemic have differed within individual countries and for specific tumour groups, with some countries responding exceptionally well under the circumstances. Emerging from the clamor are examples of best practices that provide the basis for further discussion.
This webinar will highlight:
- The significance of identifying and sharing these effective approaches to minimise the negative collateral impact of the COVID-19 pandemic on cancer screenings and testing
- The importance of building resilience into health systems for longer-term advancement of cancer care